2022. Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s74. DOI:https://doi.org/10.25251/skin.6.supp.74.